Back to Search Start Over

Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias

Authors :
Satu Maria Remes
Johanna Arola
Tiina Vesterinen
Caj Haglund
Helena Leijon
Department of Pathology
HUSLAB
Institute for Molecular Medicine Finland
Helsinki Institute of Life Science HiLIFE
University Management
HUS Abdominal Center
Department of Surgery
II kirurgian klinikka
CAN-PRO - Translational Cancer Medicine Program
Research Programs Unit
University of Helsinki
Source :
J Histochem Cytochem
Publication Year :
2019
Publisher :
SAGE Publications, 2019.

Abstract

Neuroendocrine neoplasias (NENs) are known to express somatostatin receptors (SSTRs) 1–5, which are G-protein-coupled cell membrane receptors. Somatostatin receptor imaging and therapy utilizes the SSTR expression. Synthetic somatostatin analogs with radioligands are used to detect primary tumors, metastases, and recurrent disease. Receptor analogs are also used for treating NENs. Furthermore, commercially available SSTR antibodies can be used for the immunohistochemical (IHC) detection of SSTRs. We investigated different SSTR antibody clones applying diverse IHC protocol settings to identify reliable clones and feasible protocols for NENs. A tissue microarray including NENs from 12 different primary sites were stained. Only UMB clones were able to localize SSTR on the cell membranes of NENs. SSTR2 (UMB1) emerged as the most common subtype followed by SSTR5 (UMB4) and SSTR1 (UMB7). SSTR3 (UMB5) expression was mainly cytoplasmic. Yet, SSTR4 expression was weak and located primarily in the cytoplasm. Thus, appropriate IHC protocols, including proper positive and negative controls, represent requirements for high-quality NEN diagnostics and for planning personalized therapy.

Details

Language :
English
Database :
OpenAIRE
Journal :
J Histochem Cytochem
Accession number :
edsair.doi.dedup.....7153663f2654de92c779e982927a16ff